Statins Reduce Cardiovascular Events, Death Even With Adverse Reactions
Overall, 26.5% of 7604 patients for whom a different statin was prescribed after the adverse reaction had a documented adverse reaction to the second statin.
HealthDay News — For patients with an adverse reaction to a statin, continued statin prescriptions are associated with lower incidence of cardiovascular events and death, according to a study published in the Annals of Internal Medicine.
Huabing Zhang, MD, from the Peking Union Medical College Hospital in Beijing, and colleagues conducted a retrospective cohort study to examine the correlation between continuation of statin therapy after an adverse reaction and clinical outcomes. Participants had a presumed adverse reaction to a statin between 2000 and 2011.
The researchers found that 81% of the adverse reactions to statins were identified from electronic provider notes. Overall, 70.7% of the 28,266 study patients continued receiving statin prescriptions after the adverse reaction.
The cumulative incidence of the composite primary outcome (time to a cardiovascular event [myocardial infarction or stroke] or death) was 12.2% and 13.9% for patients with continued statin prescriptions vs those without (difference, 1.7%; 95% confidence interval, 0.8% to 2.7%; P <.001) at 4 years after the presumed adverse event. Overall, 26.5% of 7604 patients for whom a different statin was prescribed after the adverse reaction had a documented adverse reaction to the second statin; 84.2% of those patients continued receiving statin prescriptions.
"Continued statin prescriptions after an adverse reaction were associated with a lower incidence of death and cardiovascular events," the authors write.
Two authors disclosed financial ties to the pharmaceutical industry.
Zhang H, Plutzky J, Shubina M, Turchin A. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann Intern Med. 2017 Jul 25. doi: 10.7326/M16-0838.